Last reviewed · How we verify
Syringe with exenatide suspension — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Syringe with exenatide suspension (Syringe with exenatide suspension) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Syringe with exenatide suspension TARGET | Syringe with exenatide suspension | AstraZeneca | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Syringe with exenatide suspension CI watch — RSS
- Syringe with exenatide suspension CI watch — Atom
- Syringe with exenatide suspension CI watch — JSON
- Syringe with exenatide suspension alone — RSS
Cite this brief
Drug Landscape (2026). Syringe with exenatide suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/syringe-with-exenatide-suspension. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab